To my new found pen pal I leave this thought with you...
ROSG has failed to deliver since inception
Has lost 98% of it value since the IPO
Management has performed quite questionably on not one but several occasions at long investors peril.
I do believe in MiRNA technology but the company has a history of performance which is quite dismal.
15 years in operation and not 1 red cent of profits!
Is the company making progress yes- But at what cost.
ROSG is a speculation play at best. Putting your hard earned retirement and weekly 401K into this
upside down business plan is ludicrist. Many other investments which actually return LongTerm gains
are a better play in a topped out market.
You think ROSG has performed badly thus far-
Wait till the DOW hits 11,000 on a swift correction and see where ROSG is at then.
This market has been kicking butt for 5 years and ROSG is stuck in the mud.
To slow of growth. Misunderstood technology not yet widely adapted.
It will take many more moons to capture market share and sales to break into profitability
Hence the selloff-
Hence the rush to exit ROSG
9% slam today and your cheerleading success
Met expectations- FMI, CGIX, TROV, SGEN, MYRD
Fantastic plays - DNA rules right now.
You are years away from success here- sorry
mrbub, I disagree with your comment on several levels. First, you are offering opinions, which is fine, but they are not "facts". Claiming they are facts is specious. Provide evidence for your claims, and then they will qualify as facts. For example, you state that these salaries are out of line with other exec salaries in the biotech industry, but where is the evidence? I'd have to see the salaries of several other company executives along side Berlin's salary to make an honest evaluation. You offer no such comparative evidence.
Next, your opinion that financials are the catalyst for today's sell-off is also unsubstantiated. Who says they are? I haven't seen any analyst's comments to that effect. And if the financials you elucidate are the problem, the problem existed long before today, it's nothing new, so it cannot explain today's sell-off.
No, I've seen exactly this knee-jerk action in a stock price after an earnings release and cc too many times before, in all kinds of industries not just biotech. Sometimes it was a financial problem, such as an earnings miss, sometimes it was clearly something else. .
I maintain that the sell-off today was that "something else," and merely caused by short-term traders who jumped in over the past week, gambling that an earnings upside surprise would be a tradable event. When the company merely "met expectations," and didn't exceed them, the traders bailed. They knew the news was not interesting enough to bring in new traders, or investors for that matter.. Show's over, no sense hanging around any longer. Or better yet, time to short the stock for a while, there are bound to be a few weak hands running for the exits.
We will see in the next two weeks who is right. If the stock price does not regain its upward bias by the end of the month, I'll concede that your opinions (not your facts) were more correct than my opinions..
Mike- you know better than most here rosg financials are the concern. they are leveraging their technology, and in some regards paying for it to be leveraged in collaborations. going forward their expenses far exceed sales revenue.
its finanacial business model is upside down and too slowly correcting.
it makes not sense to invest new money here until the proof is in the pudding
and management put their skin in the game. salaries are way out of line per the performance of the company.
that is a fact.
You are half right. I did not mean skewered exactly, but was creating a portmanteau word combining skewered and word that probably would have kept the post from being listed. And as to the lawyers, well, don't even go there.
Earnings accelerating but clearly the burn rate and rate of profitability
will clash again in the near future unless sales change signifigantly.
rosg is a patent it company
rmbs was the same with dram in the 90's
did quite well actually
rosg is likely 3 years out to profitability
as sales increase cost of processing skyrockeys
return on investment years away
You mean skewered - not by wall street but by lawyers who don't want to put in the work to get the recovery shareholders deserve.
This is why I am glad I found these guys. Lost $500, made back $1800. Check out Ultimate Stock Alerts (find them in Google search)
Have you ever been involved in a class action law suit for recovery of funds lost when an investment went bad? I have, and after hours of paper work, I received less than a penny on the dollar lost. Just another way the small investor gets "skewed" by Wall Street.
what assets down and what liabilities are up? They got a boatload of cash now and no liabilities to be concerned with. But Berlin is overpaid. Yet he is doing utmost to turn this co. around you can't deny that, can you?
Under $3.00? Seriously? Down 50% since flooding the market with 40% more stock. Down 99% since flooding the market years ago with more and more shares to finance the ongoing quest to formulate marketable products. This is a company that went public way too early and all of the dilution which should have occurred while it was private is being inflicted upon public shareholders. I just spoke to a shareholder's rights lawyer in New York and asked him to investigate whether there was illicit short selling or insider sales shortly prior to the dilutive secondary offerings. If so, I told him I would serve as lead plaintiff.
Yeah, let's give the R&D people in Israel more money to develop products that Ken Berlin can't sell. Brilliant! I couldn't hear the company he was with, but I think he said Dewey, Cheatham & Howe Investments. He was special!
Good observation. I would say 20 years too early at minimum. But beyond that, not clear if products they currently have will ever reach critical mass in revenue considering the boat load of money already poured into this sink hole of a bio company.
Conference call was upbeat and though I don't fully understand the science, it sounds promising and a worthwhile addition to the health care market. The potential to reduce unnecessary surgeries seems to be one of the best marketing strategies. Financials continue to be of concern, but if this company didn't have the baggage of poor past performance, I think market response would be positive.
So my question.... why, almost as soon as the prepared presentation was over did the share price drop below 3? My guess: folks were waiting to sell if there wasn't anything dramatically new and of course selling begets more selling. Ironic, isn't it? Selling is like a cancer.
New Product sales are more of an exponential curve if the product is successful. 2 x 2013 sales is hardly worth talking about. It needs to be 4 to 5 times and should be soon if the product is a successful product. But if the result don't come close to justifying the cost, then sales will be non existent. Furthermore the relation and reputation built on these first two products ( one in particular) will give traction to the Thyroid Testing and other pipeline products in the future and accelerate their time to market. The cash on hand to 2017 was a very big and maybe the only big news in the whole release.
I can only hope that they bought back their 9 million plus shares at around 3.10 seeing as they sold them for 4.22 per share.